CD47 and acute myeloid leukemia: In addition to the aforementioned macrophage-targeting strategies, there is a substantial body of evidence suggesting that checkpoint inhibition at the CD47-SIRPα level, is a highly promising therapeutic approach for various cancers, including AML.